HALOZYME THERAPEUTICS INC (HALO)       59.44  +2.04 (+3.55%)

59.44  +2.04 (+3.55%)

US40637H1095 - Common Stock - After market: 59.44 0 (0%)

HALOZYME THERAPEUTICS INC59.44

NASDAQ:HALO (12/2/2022, 7:00:01 PM)+2.04 (+3.55%)

After market: 59.44 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-08 2022-11-08/amc Earnings (Next) 02-20 2023-02-20
Ins Owners 0.93% Inst Owners 97.12%
Market Cap 8.04B Shares 135.21M
PE 27.52 Fwd PE 18.81
Dividend Yield N/A Analysts 77.5
IPO 01-30 2003-01-30

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

HALO Daily chart

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. The company is headquartered in San Diego, California and currently employs 145 full-time employees. The company went IPO on 2003-01-30. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The firm's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The firm's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The firm's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. The rHuPH20 can be applied as a drug delivery platform to increase dispersion and absorption of other injected drugs and fluids, potentially reducing the treatment burden.

Company Info

HALOZYME THERAPEUTICS INC

11388 Sorrento Valley Rd

San Diego CALIFORNIA 92121-1345

P: 18587948889.0

CEO: Helen I. Torley

Employees: 145

Website: https://www.halozyme.com/

HALO News

News Image6 days ago - Seeking AlphaHALO stock initiated Overweight at Wells Fargo on partnerships, patents (NASDAQ:HALO)

Pgiam/iStock via Getty Images Wells Fargo launched its coverage on Halozyme (NASDAQ:HALO) on Monday with an Overweight recommendation ruling out concerns on an upcoming patent cliff and...

News Image23 days ago - Investor's Business DailyStock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review

Bitcoin hit a two-year low while Meta and Tesla were in focus.

News Image26 days ago - Halozyme Therapeutics, Inc.HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today reported its financial and operating results for the third quarter ended...

News Imagea month ago - Halozyme Therapeutics, Inc.Halozyme to Report Third Quarter 2022 Financial and Operating Results

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2022 financial and operating results...

News Image2 months ago - Market News VideoHalozyme Therapeutics Larger Than S&P 500 Component Alaska Air Group

HALO Twits

Here you can normally see the latest stock twits on HALO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example